Accord BioPharma Inc, the specialized arm of Intas Pharmaceuticals Ltd that focuses on therapies for oncology, immunology and critical care, announced that Express Scripts, one of the largest pharmacy benefit managers in the United States, has placed IMULDOSA on its major commercial formularies starting September 5, 2025.
Health Technology Insights: Heartburn Drives Millions of Unnecessary Medical Procedures
IMULDOSA is a biosimilar to STELARA (ustekinumab) and carries the same FDA approved uses with no meaningful clinical differences from the original medicine. The product is offered in a prefilled syringe designed with patient comfort in mind along with a single dose vial for intravenous administration. Full prescribing information and safety details remain available for healthcare professionals and patients.
Being added to Express Scripts formularies marks an important step forward for patients who rely on targeted biologic treatments for plaque psoriasis, psoriatic arthritis, Crohns disease and ulcerative colitis. This update opens broader access to a therapy that has already shown strong clinical value.
Health Technology Insights: Luma Acquires Tonic to Solve Healthcare Bottlenecks
Chrys Kokino, President of Accord North America, shared that the company wants to ensure that cost is not a reason patients miss out on therapies that can improve their quality of life. He noted that inclusion in Express Scripts formularies strengthens the company’s goal of widening access to important biologic treatments and reflects its ongoing commitment to solutions that genuinely support patients.
Paul Purdy, VP and Head of Market Access at Accord BioPharma, explained that securing a place on these formularies highlights the company’s dedication to providing more affordable biologic options for people living with immune driven inflammatory conditions. He added that the team is continuing active discussions with other major pharmacy benefit managers to help more patients across the country gain access to IMULDOSA.
Health Technology Insights: House Rx Raises $55 Million to Scale In-Clinic Specialty Pharmacy Model
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
